AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen
Germany · 297 open tenders · 1,353 documented awards
Current tenders
Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Distigmine (ATC code according to WHO: N07AA03)
Deadline 31 Oct ·
Conclusion of non-exclusive drug discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient glyceryl trinitrate (ATC code according to WHO: C01DA02)
Deadline 31 Oct ·
Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a para. 8 SGB V via an open-house model for the active ingredient Certolizumab pegol (ATC code according to WHO: L04AB05)
Deadline 31 Oct ·
Conclusion of non-exclusive drug discount agreement pursuant to § 130a section 8 SGB V via an open-house model for the active ingredient Tacrolimus (ATC code according to WHO: L04AD02)
Deadline 31 Oct ·
Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Tacrolimus (ATC code according to WHO: L04AD02)
Deadline 31 Oct ·
Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a (8) SGB V via an open-house model for the active ingredient certolizumab pegol (ATC code according to WHO: L04AB05)
Deadline 31 Oct ·
Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient glyceryl trinitrate (ATC code according to WHO: C05AE01)
Deadline 31 Oct ·
Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient glyceryl trinitrate (ATC code according to WHO: C01DA02)
Deadline 31 Oct ·
Conclusion of non-exclusive drug discount agreement pursuant to § 130a Para. 8 SGB V via an open-house model for the active ingredient distigmine (ATC code according to WHO: N07AA03)
Deadline 31 Oct ·
Conclusion of non-exclusive drug discount agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient glyceryl trinitrate (ATC code according to WHO: C05AE01)
Deadline 31 Oct ·
Open-House-Verfahren "BGM-Prozesssteuerung"
Deadline 16 Nov ·
Conclusion of non-exclusive AM discount agreement pursuant to § 130a para. 8 SGB V by means of an OH model for the active ingredient beclometasone/formoterol (ATC code according to WHO: R03AK08), excluding the active substance 100µg/6µg as a metered dose aerosol
Deadline 30 Nov ·
Conclusion of non-exclusive drug discount agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active substance etanercept (ATC code according to WHO: L04AB01)
Deadline 30 Nov ·
Conclusion of non-exclusive drug discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Adalimumab (ATC code according to WHO: L04AB04)
Deadline 30 Nov ·
Conclusion of non-exclusive pharmaceutical rebate agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Natalizumab (ATC code according to WHO: L04AG03)
Deadline 30 Nov ·
Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active substance Natalizumab (ATC code according to WHO: L04AG03)
Deadline 30 Nov ·
Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a para. 8 SGB V via an open-house model for the active ingredient etanercept (ATC code according to WHO: L04AB01)
Deadline 30 Nov ·
Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Adalimumab (ATC code according to WHO: L04AB04)
Deadline 30 Nov ·
Conclusion of non-exclusive drug discount agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient infliximab for subcutaneous injection (ATC code according to WHO: L04AB02)
Deadline 31 Dec ·
Conclusion of non-exclusive drug discount agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Tiotropium bromide (ATC code according to WHO: R03BB04)
Deadline 31 Dec ·
Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a paragraph 8 SGB V by means of an open-house model for the active substance Rotigotine (ATC code according to WHO: N04BC09)
Deadline 31 Dec ·
Conclusion of non-exclusive drug rebate agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active substance brinzolamide/timolol (official ATC code: S01ED67)
Deadline 31 Dec ·
Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a paragraph 8 SGB V by means of an open-house model for the active ingredient tocilizumab (ATC code according to WHO: L04AC07)
Deadline 31 Dec ·
Conclusion of non-exclusive drug discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active substance Golimumab (ATC code according to WHO: L04AB06)
Deadline 31 Dec ·
Conclusion of non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V via an OH model for the active substance Aflibercept (ATC code according to WHO: S01LA05; excluding 114.3 mg/ml) as injection solution in a pre-filled syringe
Deadline 31 Dec ·
Conclusion of non-exclusive drug discount agreement pursuant to § 130a paragraph 8 SGB V via an open-house model for the active substance Ranibizumab (ATC code according to WHO: S01LA04) as injection solution in a pre-filled syringe
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreement pursuant to § 130a section 8 SGB V by means of an OH model for the active ingredient Aflibercept (ATC code according to WHO: S01LA05; excluding 114.3 mg/ml) as injection solution in a vial
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active substance Ranibizumab (ATC code according to WHO: S01LA04) as an injection solution in a vial
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V via an open-house model for the active ingredient Ranibizumab (ATC code according to WHO: S01LA04) as an injection solution in a vial
Deadline 31 Dec ·
Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a para. 8 SGB V via an open house model for the active ingredient Ranibizumab (ATC code according to WHO: S01LA04) as an injection solution in a pre-filled syringe
Deadline 31 Dec ·
Purchasing rhythm
Awards per year — who knows the rhythm prepares before the notice appears.
2018165
2019251
2020231
2021198
2022158
2023273
2024434
2025549
2026205
Clement What the numbers say about this buyer
- The median procedure drew just one bid (753 procedures with a bid count); 72% ended with a single bidder. Country: median 3.1 bids.n = 753
- 38% of the bids received came from small and medium-sized enterprises (38 procedures with a bid mix). Country: 75%.n = 38
- 54% of this buyer's awards went to companies that had already won here before (899 awards since 2017, spread over 414 companies). 46% went to new names.n = 899 awards since 2017
- From notice to award takes a median 490 days here (260 procedures). Country: 91 days.n = 260
- Across 140 procedures with structured selection criteria, this buyer most often required: Quality management (140 of 140), Staff qualifications (9 of 140), Professional liability insurance (6 of 140), References: services (2 of 140).n = 140
- 0% of the bids received came from other countries (38 procedures with a bid mix) — all bidders, not just the winners. Country: 3%.n = 38
- 1% of awards went to companies from abroad (899 awards with a known winner country). National average: 1%.n = 899
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Expected next awards
From the rhythm of past awards per sector — an expectation, not an announcement. Hit rate so far: 26% of 11,200 closed expectation windows produced a notice.
- Sept 2026Medical equipment & pharma
about every 2 months · 669 awards · last Jul 2026 to ViiV Healthcare GmbH - Oct 2026Health & social work
about every 3 months · 31 awards · last Aug 2026 to Preventicus GmbH - Jul 2027Office & computing machinery
about every 19 months · 9 awards · last Dec 2025 to Ludwig Mack Produktions- und Vertriebs GmbH
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Hexal AG · Holzkirchen | 45 | 2013–2024 |
| Aliud Pharma GmbH · Laichingen | 41 | 2013–2021 |
| ratiopharm GmbH | 37 | 2016–2024 |
| betapharm Arzneimittel GmbH · Augsburg | 35 | 2013–2021 |
| axicorp Pharma B.V. · EC Den Haag | 30 | 2016–2021 |
| Abacus Medicine A/S · Kopenhagen | 28 | 2016–2021 |
| Haemato Pharm GmbH · Schönefeld | 25 | 2016–2021 |
| Zentiva Pharma GmbH · Frankfurt am Main | 24 | 2016–2021 |
| STADAPHARM GmbH · Bad Vilbel | 23 | 2013–2024 |
| Aristo Pharma GmbH · Berlin | 21 | 2013–2020 |
From 18.0M documented awards · regular winners know this buyer's requirements — that is your competition.